The FTC suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group's Optum Rx, CVS Health's Caremark and Cigna's Express Scripts.
  • The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while “artificially” inflating costs for patients.
  • The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts, and their affiliated group purchasing organizations.
  • The FTC may also recommend suing insulin manufacturers Eli Lilly, Sanofi and Novo Nordisk in the future.
  • @irotsomaEnglish
    11•3 months ago

    I work for one of the parent companies of one of them and damn the propaganda has been crazy trying to discredit everything about the reports and the cases against them and trying to get employees to write to politicians and propagandize for them. They must be actually worried about the hit to profits over this. I mean it’s not like any tiny little fine will be a concern.